2nd Quarter - Report

ARENTFOX SCHIFF LLP for KEMPHARM, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —

Contacted: Office of Natl Drug Control Policy (NDCP); Vice President of the U.S.; SENATE; HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2025 (115th), H.R. 2430 (115th)

Health Issues HCR

Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse legislation

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
NORMAN FREDERICK LENT —
SONJA NESBIT —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Natl Drug Control Policy (NDCP); Health & Human Services, Dept of (HHS); Vice President of the U.S.; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.